Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK.
Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK; Cellular Genetics, Wellcome Sanger Institute, Cambridge, UK.
Cell Rep. 2023 Aug 29;42(8):112991. doi: 10.1016/j.celrep.2023.112991. Epub 2023 Aug 16.
Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70-75) who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 (median age 66, range 54-69) at 1 month post booster. Impaired neutralization potency and breadth post third dose in the elderly is associated with circulating "atypical" spike-specific B cells expressing CD11c and FCRL5. However, when considering individuals who received three doses of mRNA vaccine, we did not observe differences in neutralization or enrichment in atypical B cells. This work highlights the finding that AdV and mRNA COVID-19 vaccine formats differentially instruct the memory B cell response.
老年人在初次接种疫苗后出现的反应不理想，但关于年龄对加强型第三针反应的影响的信息很少。在这里，我们发现，与 70 岁以下的人（中位年龄 66 岁，范围 54-69 岁）相比，接受了 AZD1222 双价基础免疫和 mRNA 疫苗加强型第三针的 70 岁及以上（中位年龄 73 岁，范围 70-75 岁）人群在加强针后 1 个月时针对 SARS-CoV-2 刺突假病毒的中和抗体反应显著降低。在老年人中，第三针后中和作用的效力和广度受损与循环中表达 CD11c 和 FCRL5 的“非典型”刺突特异性 B 细胞有关。然而，当考虑接受三剂 mRNA 疫苗的个体时，我们没有观察到中和作用或非典型 B 细胞的富集存在差异。这项工作强调了这样一个发现，即 AdV 和 mRNA COVID-19 疫苗制剂以不同的方式指导记忆 B 细胞反应。
